- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 941KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 318KB)
Ribociclib – November 2024
Ribociclib; Tablet 200 mg; Kisqali®
Last updated
30 May 2025